From Data Signals To Endpoint Success: How Integrated Analytics And Rater Training Transformed An Atopic Dermatitis Trial

By Maria Visser, Todd Everhart, Marcela Roy, Dr. Alan Kott

Dermatology trials pose distinctive challenges, as their clinician-rated endpoints rely heavily on expert judgment, precise interpretation, and methodological consistency across global sites. When a biotechnology sponsor initiated a large Phase 2b atopic dermatitis study spanning more than 110 sites and numerous languages, the complexity made data quality a central operational concern. Signant deployed its PureSignal Analytics platform to continuously monitor clinical outcome assessment data across more than 350 patients and 10 instruments, providing both high-level surveillance and detailed clinical review.

As the study progressed, real-time analytics uncovered patterns pointing to inconsistencies in how raters applied scoring rules and interpreted scales. These insights prompted deeper collaboration between the sponsor and Signant, shifting the work beyond data review alone. Instead of relying on standard refresher materials, the team developed interactive, evidence-based rater training tailored directly to the issues surfaced in the live data. Training incorporated practical examples, relationships between scales, and real-world anomalies, while being delivered flexibly across global sites.

The engagement evolved into an integrated model in which data analytics and targeted education informed one another, helping teams respond quickly to emerging risks and support more dependable clinician-scored endpoints.

See how this coordinated approach can strengthen reliability in complex, clinician-rated trials.